Finally, the results suggested that the expression of six genes including IRF1, JAK2, CD8A, IRF8, STAT5B, and SELL had a significant ability to distinguish the responders from non-responders to anti-PD-1 therapy in melanoma with AUC > 0.6 and pAUC > 0.7 (Figure 4). This evidence concerns the gene IRF1 and melanoma.